Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03121339 · ClinicalTrials.gov registry record · Phase 1
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
A Phase 1 study, sponsored by Vaxart.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03121339 is a Phase 1 study that has completed, run by Vaxart. The registered enrollment target is 8 participants.
The verdict
NCT03121339, a Phase 1 study, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a phase 1 open-label pharmacodynamics study in healthy adults. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, has an impact on delivery location. The secondary objective is to evaluate delivery with fasting versus fed status.
Interventions
- BIOLOGICAL VXA-A1.1 H1 Tablet Vaccine (small)
- BIOLOGICAL VXA-A1.1 H1 Tablet Vaccine (large)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2018-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03121339
The ClinicalTrials.gov registry entry for NCT03121339 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VXA-A1.1 H1 Tablet Vaccine (small) is the first listed.
NCT03121339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03121339 about?
NCT03121339 is a clinical study titled "Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults". This is a phase 1 open-label pharmacodynamics study in healthy adults. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, has an impact on delivery location. The secondary objective is to evaluate delivery with fasti...
What is the current status of trial NCT03121339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-03-31. Estimated completion is 2018-04-03.
What interventions are being tested in trial NCT03121339?
The interventions under investigation include: VXA-A1.1 H1 Tablet Vaccine (small) (BIOLOGICAL), VXA-A1.1 H1 Tablet Vaccine (large) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03121339?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.